Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042769 · ClinicalTrials.gov registry record · Phase 3
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,226
- Enrollment target
NCT01042769: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT01042769 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 7,226 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (836% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01042769, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,226 participants
- Enrollment target
Study Summary
This double-blind, parallel, two-arm study will evaluate the potential to reduce cardiovascular risk, the tolerability and long-term safety profile of aleglitazar compared to placebo on top of standard care in patients with recent acute coronary syndrome (ACS) and type 2 diabetes mellitus. Patients will be randomized to receive either aleglitazar or placebo once daily as oral doses. The study will last until at least 950 events occur, but time on study treatment will be for at least 2.5 years.
Interventions
- DRUG Placebo
- DRUG Aleglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,226 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
What the finished NCT01042769 record still lists
NCT01042769 is an interventional study that assigns participants to a tested intervention. Its 7,226 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (836% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01042769 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01042769 about?
NCT01042769 is a clinical study titled "A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus". This double-blind, parallel, two-arm study will evaluate the potential to reduce cardiovascular risk, the tolerability and long-term safety profile of aleglitazar compared to placebo on top of standard care in patients with recent acute coronary syndrome (ACS) and type 2 diabetes mellitus. Patients ...
What is the current status of trial NCT01042769?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,226 participants. The study started on 2010-02. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01042769?
The interventions under investigation include: Placebo (DRUG), Aleglitazar (DRUG).
Who is sponsoring clinical trial NCT01042769?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01042769's enrollment target sits among peer trials
7,226 34th of 2000 higher than 1,967 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05049837 · 7,200 participants
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
- NCT06714929 · 7,200 participants · NA
Advancing Water Security: A Community Participatory School-Based Hydration Intervention
- NCT06843720 · 7,100 participants · NA
Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems
- NCT02915198 · 7,410 participants · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia